BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
January 02 2019 - 8:00AM
Business Wire
BioTime, Inc. (NYSE American: BTX), a clinical-stage
biotechnology company focused on degenerative diseases, today
announced that Brian M. Culley, Chief Executive Officer of BioTime
will be presenting at the 2019 Biotech Showcase Investor Conference
on January 7th, 2019 at 9am Pacific Time at the Hilton San
Francisco Union Square Hotel in the Franciscan A Ballroom in San
Francisco, CA.
“Our vision is to build BioTime into the premiere cell therapy
company, pioneering whole-cell transplants to address unmet medical
conditions such as macular degeneration and spinal cord injury1,
which have not yielded to small molecule approaches,” stated Brian
M. Culley, Chief Executive Officer of BioTime. “Awareness of our
mission is vital and our presentation at Biotech Showcase is one of
our first opportunities to share our updated plans with a broad
audience and build support for BioTime’s short- and long-term
objectives. Our recent transactions involving AgeX Therapeutics
Inc. (“AGE”) demonstrates our ability to convert intellectual
property from our platform into capital for our core programs. And
pending a successful close of the proposed acquisition of Asterias
Biotherapeutics, Inc. (“AST”), we will broaden our pipeline next
quarter with two additional clinical-stage cell therapy assets. We
are excited about our future and believe that delivering on our
stated milestones at each stage of corporate and clinical
development and increasing our visibility through active and
strategic engagements will make BioTime a highly successful
company.”
Interested parties can access a live audio webcast on the Events
and Presentations section of BioTime’s website. An archived
presentation will be available on the website for 30 days. The 2019
Biotech Showcase is an investor and networking conference devoted
to providing private and public biotechnology and life sciences
companies with an opportunity to present to, and meet with,
investors and executives in one place during the course of the 37th
Annual J.P. Morgan Annual Healthcare Conference. Interested parties
may follow @EBDGroup on Twitter and use #BiotechShowcase
for the latest conference updates.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused
on the development and commercialization of novel therapies for the
treatment of degenerative diseases. BioTime’s pipeline is based on
two platform technologies which encompass cell replacement and
cell/drug delivery. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium transplant
therapy in Phase 2 development for the treatment of dry age-related
macular degeneration, the leading cause of blindness in the
developed world. BioTime’s lead cell delivery clinical program is
Renevia®, an investigational medical device being developed as an
alternative for whole adipose tissue transfer procedures.
BioTime common stock is traded on the NYSE American and TASE
under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company on
Twitter, LinkedIn, Facebook, YouTube, and Google+. To
receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert
list: http://news.biotime.com.
Additional Information and Where to Find It
This communication is being made in respect of the proposed
business combination involving BioTime, Inc. and Asterias
Biotherapeutics, Inc. In connection with the proposed transaction,
BioTime and Asterias plan to file documents with the U.S.
Securities and Exchange Commission (the “SEC”), including the
filing by BioTime of a Registration Statement on Form S-4
containing a Joint Proxy Statement/Prospectus and each of BioTime
and Asterias plan to file with the SEC other documents regarding
the proposed transaction. INVESTORS AND SECURITY HOLDERS OF BIOTIME
AND ASTERIAS ARE URGED TO CAREFULLY READ THE JOINT PROXY
STATEMENT/PROSPECTUS (WHEN AVAILABLE) AND OTHER DOCUMENTS FILED
WITH THE SEC BY BIOTIME AND ASTERIAS BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and
security holders may obtain free copies of these documents (when
they are available) and other documents filed with the SEC at the
SEC’s web site at www.sec.gov and by contacting BioTime Investor
Relations at (510) 871-4188 or Asterias Investor Relations at (510)
456-3892. Investors and security holders may obtain free copies of
the documents filed with the SEC on BioTime’s website at
www.biotimeinc.com or Asterias’ website at
www.asteriasbiotherapeutics.com or the SEC’s website at
www.sec.gov. BioTime, Asterias and their respective directors and
executive officers may be deemed participants in the solicitation
of proxies with respect to the proposed transaction. Information
regarding the interests of these directors and executive officers
in the proposed transaction will be included in the Joint Proxy
Statement/Prospectus described above. Additional information
regarding the directors and executive officers of BioTime is also
included in BioTime’s proxy statement for its 2018 Annual Meeting
of Shareholders, which was filed with the SEC on March 29, 2018,
and additional information regarding the directors and executive
officers of Asterias is also included in Asterias’ proxy statement
for its 2018 Annual Meeting of Stockholders, which was filed with
the SEC on April 30, 2018, respectively.
No Offer or Solicitation
This document does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote or approval nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended.
Forward-Looking Statements
Certain statements in this communication, including statements
relating to the Merger Agreement, the Merger and the other
transactions contemplated by the Merger Agreement and the combined
company’s future financial condition performance and operating
results, strategy and plans, including the design, status , funding
and timing of the clinical trials and further development and
potential of the product candidates are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 giving BioTime’s and Asterias’ expectations or
predictions of future financial or business performance or
conditions. These forward-looking statements are subject to
numerous assumptions, risks and uncertainties which change over
time. Forward-looking statements speak only as of the date they are
made and we assume no duty to update forward-looking statements. In
addition to factors previously disclosed in BioTime’s and Asterias’
reports filed with the SEC and those identified elsewhere in this
communication, the following factors, among others, could cause
actual results to differ materially from forward-looking statements
and historical performance: the ability to meet closing conditions
to the Merger, including requisite approval by BioTime’s and
Asterias’ stockholders, on a timely basis or at all; delay in
closing the Merger; the ultimate outcome and results of integrating
the operations of BioTime and Asterias and the ultimate ability to
realize synergies and other benefits; business disruption following
the Merger; the availability and access, in general, of funds to
fund operations and necessary capital expenditures. More
information on potential factors that could affect our results is
included from time to time in the SEC filings and reports of
BioTime and Asterias, including the risks identified under the
sections captioned “Risk Factors” in BioTime’s quarterly report on
Form 10-Q filed with the SEC on November 8 and Asterias’ annual
report on Form 10-K for the year ended December 31, 2017 filed with
the SEC on March 15, 2018, and Asterias’ quarterly report on Form
10-Q for the quarter ended September 30, 2018, which Asterias
expects to file on November 9, 2018.
1 Bio Time does not currently own this product and this
discussion assumes the closing of the Merger, which is subject to
certain closing conditions, including obtaining the approval of Bio
Time shareholders and Asterias stockholders.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190102005120/en/
BioTime Inc. IRIoana C. Hone(ir@biotimeinc.com)510-871-4188
Solebury Trout IRGitanjali Jain
Ogawa(Gogawa@troutgroup.com)646-378-2949
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024